ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma

Lee, Nan; Xia, Xuelian; Meng, Hui; Zhu, Weiliang; Wang, Xiankai; Zhang, Tianyuan; Zhang, Chanyuan; Zhang, Jian*; Luo, Peng*南方医科大学
Cancer Biomarkers2021DOI: 10.3233/CBM-201564
4被引6阅读
引用收藏
分享

摘要

BACKGROUND: DNA methylation plays a vital role in modulating genomic function and warrants evaluation as a biomarker for the diagnosis and treatment of lung squamous cell carcinoma (LUSC). @@@ OBJECTIVE: In this study, we aimed to identify effective potential biomarkers for predicting prognosis and drug sensitivity in LUSC. @@@ METHODS: A univariate Cox proportional hazards regression analysis, a random survival forests-variable hunting (RSFVH) algorithm, and a multivariate Cox regression analysis were adopted to analyze the methylation profile of patients with LUSC included in public databases: The Cancer Genome Atlas (TCGA), and the Gene Expression Omnibus (GEO). @@@ RESULTS: A methylated region consisting of 3 sites (cg06675147, cg07064331, cg20429172) was selected. Patients were divided into a high-risk group and a low-risk group in the training dataset. High-risk patients had shorter overall survival (OS) (hazard ratio [HR]: 2.72, 95% confidence interval [CI]: 1.82-4.07, P < 0.001) compared with low-risk patients. The accuracy of the prognostic signature was validated in the test and validation cohorts (TCGA, n = 94; GSE56044, n = 23). Gene set variation analysis (GSVA) showed that activity in the cell cycle/mitotic, ERBB, and ERK/MAPK pathways was higher in the high-risk compared with the low-risk group, which may lead to differences in OS. Interestingly, we observed that patients in the high-risk group were more sensitive to gemcitabine and docetaxel than the low-risk group, which is consistent with results of the GSVA. @@@ CONCLUSION: We report novel methylation sites that could be used as powerful tools for predicting risk factors for poorer survival in patients with LUSC.

学科与关键词

关键词
Lung squamous cell carcinomamethylated sitesoverall survivalprognosissignature
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cancer Biomarkers
发表日期
2021
卷期
第 30 卷, 第 1 期
页码
63-73
DOI
10.3233/CBM-201564
语言
ENGLISH
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81672267, 81871859]; Natural Science Foundation of Guangdong Province [2016A030313632]

作者

  • L

    Lee, Nan (第一作者)

    southern med univ

  • X

    Xia, Xuelian

查看全部 9 位作者收起作者
  • M

    Meng, Hui

    southern med univ

  • Z

    Zhu, Weiliang

    southern med univ

  • W

    Wang, Xiankai

    southern med univ

  • Z

    Zhang, Tianyuan

    southern med univ

  • Z

    Zhang, Chanyuan

    southern med univ

  • Z

    Zhang, Jian (通讯)

    southern med univ

  • L

    Luo, Peng (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417